Table 1.

Demographic and disease characteristics in the enrolled set (N = 20)

CharacteristicN (%)
Age, y  
 Mean 61.5 
 Standard deviation 12.5 
 Range 39-80 
Sex  
 Male 10 (50) 
 Female 10 (50) 
Initial histology (local)  
 CD20+ FL grade 1 9 (45) 
 CD20+ FL grade2 7 (35) 
 CD20+ FL grade 3a 1 (5) 
 CD20+ FL (grade unknown) 3 (15) 
No. of prior treatments  
 Median 2.0 
 Range 1-5 
Ann Arbor stage  
 1-2 3 (15) 
 3-4 17 (85) 
Performance status (ECOG)  
 0 16 (80) 
 1 4 (20) 
Bone marrow involvement 6 (40)* 
LDH, IU/L  
 Normal 13 (65) 
 >Upper limit of normal 7 (35) 
Bulk >5 cm  
 No 15 (75) 
 Yes 5 (25) 
Calculated FLIPI score  
 0 2 (10) 
 1 3 (15) 
 2 6 (30) 
 3 7 (35) 
 4 1 (5) 
 5 1 (5) 
Refractory to rituximab  
 No 12 (60) 
 Yes 8 (40) 
Refractory to prior lymphoma therapy  
 No 16 (80) 
 Yes 4 (20) 
CharacteristicN (%)
Age, y  
 Mean 61.5 
 Standard deviation 12.5 
 Range 39-80 
Sex  
 Male 10 (50) 
 Female 10 (50) 
Initial histology (local)  
 CD20+ FL grade 1 9 (45) 
 CD20+ FL grade2 7 (35) 
 CD20+ FL grade 3a 1 (5) 
 CD20+ FL (grade unknown) 3 (15) 
No. of prior treatments  
 Median 2.0 
 Range 1-5 
Ann Arbor stage  
 1-2 3 (15) 
 3-4 17 (85) 
Performance status (ECOG)  
 0 16 (80) 
 1 4 (20) 
Bone marrow involvement 6 (40)* 
LDH, IU/L  
 Normal 13 (65) 
 >Upper limit of normal 7 (35) 
Bulk >5 cm  
 No 15 (75) 
 Yes 5 (25) 
Calculated FLIPI score  
 0 2 (10) 
 1 3 (15) 
 2 6 (30) 
 3 7 (35) 
 4 1 (5) 
 5 1 (5) 
Refractory to rituximab  
 No 12 (60) 
 Yes 8 (40) 
Refractory to prior lymphoma therapy  
 No 16 (80) 
 Yes 4 (20) 

ECOG, Eastern Cooperative Oncology Group; FLIPI, Follicular Lymphoma International Prognostic Index; LDH, lactic dehydrogenase.

*

n = 15.

or Create an Account

Close Modal
Close Modal